Adma Biologics (ADMA) Cash from Investing Activities (2011 - 2025)
Adma Biologics' (ADMA) quarterly Cash from Investing Activities came in at -$276000.0 in Q4 2025, up 89.96% YoY from -$145291.0 in Q4 2024, and up 98.08% on a QoQ basis from -$14.4 million in Q3 2025.
Adma Biologics (ADMA) Cash from Investing Activities (2011 - 2025) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Cash from Investing Activities data on file, last reported at -$276000.0 in Q4 2025.
- Quarterly Cash from Investing Activities rose 89.96% year-over-year to -$276000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$21.9 million (down 155.29% YoY) and the FY2025 annual result came in at -$21.9 million, down 155.29% from the prior year.
- Cash from Investing Activities climbed to -$276000.0 in Q4 2025, from -$14.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$276000.0 in Q4 2025 to a low of -$14.4 million in Q3 2025.
- A 5-year average of -$3.1 million and a median of -$2.7 million in 2021 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 89.96% in 2025, down 1208.56% in 2025.
- Tracing ADMA's Cash from Investing Activities over 5 years: stood at -$3.7 million in 2021, then retreated by 1.98% to -$3.7 million in 2022, then surged by 62.46% to -$1.4 million in 2023, then slumped by 95.45% to -$2.8 million in 2024, then surged by 89.96% to -$276000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$276000.0 (Q4 2025), -$14.4 million (Q3 2025), and -$2.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -276,000.00 |
| Dec 31, 2025 | -276,000.00 |
| Sep 30, 2025 | -14.37 Mn |
| Sep 30, 2025 | -14.37 Mn |
| Jun 30, 2025 | -2.53 Mn |
| Jun 30, 2025 | -2.53 Mn |
| Mar 31, 2025 | -4.72 Mn |
| Mar 31, 2025 | -4.72 Mn |
| Dec 31, 2024 | -2.75 Mn |
| Dec 31, 2024 | -2.75 Mn |
| Sep 30, 2024 | -1.10 Mn |
| Sep 30, 2024 | -1.10 Mn |
| Jun 30, 2024 | -2.37 Mn |
| Jun 30, 2024 | -2.37 Mn |
| Mar 31, 2024 | -2.36 Mn |
| Mar 31, 2024 | -2.36 Mn |
| Dec 31, 2023 | -1.41 Mn |
| Dec 31, 2023 | -1.41 Mn |
| Sep 30, 2023 | -757,000.00 |
| Sep 30, 2023 | -757,000.00 |